Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

US9845363B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Alla Pritsker · Cambridge, US
• Patrick Grailhe · Paris, FR
• Alexey Rak · Paris, FR
• Magali Mathieu · Choisy-le-Roi, FR
• Christopher Ryan Morgan · Southborough, US
• Nicolas Baurin · Arpajon, FR
• Bruno Poirier · Paris, FR
• Cyril Daveu · Paris, FR
• Francis Duffieux · Paris, FR
• Han Li · Xi'an, CN
• Dorothea Kominos · Millington, US
• Philip Janiak · Gif-sur-Yvette, FR

Key dates

• Filing date: Aug 13, 2014
• Grant date: Dec 19, 2017
• Expiry date: Aug 13, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.